Results 101 to 110 of about 10,491 (187)

Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents

, 2013
James Nuttall,1 Tammy Meyers,2 Brian Eley11Paediatric Infectious Diseases Unit, Red Cross War Memorial Children's Hospital and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa; 2Department of Paediatrics ...
Nuttall J, Meyers T, Eley B
core  

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects

, 2011
Objectives: Limited studies in healthy volunteers and in HIV-1-infected patients have shown that raltegravir pharmacokinetics are characterized by high inter-patient variability.
M. Pellegrini, E. Clementi., S. Landonio, S. Fucile, C. Gervasoni, D. Cattaneo, V. Cozzi, P. Meraviglia, M. Galli, E. Clementi, S. Baldelli   +10 more
core   +1 more source

Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-Infected Patients

, 2012
Stepwise multiple regression analyses were applied to 50 raltegravir pharmacokinetic profiles from 50 HIV patients with the goal to identify limited sampling strategies for the prediction of drug area under the time-concentration curve (AUC(0-12 ...
Serena Fucile, C. Gervasoni, D. Cattaneo, S. Baldelli, Dario Cattaneo, D. Ripamonti, S. Landonio, S. Fucile, Emilio Clementi, Sara Baldelli, V. Cozzi, Cristina Gervasoni, Simona Landonio, P. Meraviglia, Paola Meraviglia, Valeria Cozzi, E. Clementi, Diego Ripamonti   +17 more
core   +1 more source

Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals

, 2010
Background Atazanavir plus raltegravir 300/400 mg twice daily is being explored as a ritonavir- and nucleoside- sparing treatment strategy. The pharmaco-kinetics and safety of this combination in healthy individuals were evaluated.
Li Zhu, Joan Butterton, Michele Stonier, Anna Persson, Sheila Breidinger, Richard Bertz, Jenny Zhang, Wendy Comisar, Deborah Panebianco   +8 more
core   +1 more source

Pharmacokinetics and Pharmacogenomics of Once-Daily Raltegravir and Atazanavir in Healthy Volunteers

, 2010
Atazanavir inhibits UDP-glucuronyl-transferase-1A1 (UGT1A1), which metabolizes raltegravir, but the magnitude of steady-state inhibition and role of the UGT1A1 genotype are unknown. Sufficient inhibition could lead to reduced-dose
Ashley Margol, Decosterd, Laurent, Aurélie Fayet, Lee, Janice Soo Fern, di Iulio, J., Janice Soo Fern Lee, Alexandra Calmy, Michael Neely, Julia di Iulio, Roger Jelliffe, Lee Janice Soo, Fern, Kanani, Meera, Tido von Schoen-Angerer, von Schoen-Angerer, T., Jelliffe, R., Meera Kanani, von Schoen-Angerer, Tido, Laurent Decosterd, di Iulio, Julia, Margol, Ashley, Calmy, Alexandra, Jelliffe, Roger, Neely, Michael, Fayet, Aurelie   +23 more
core   +1 more source

Variability of raltegravir plasma levels in the clinical setting

, 2013
Therapeutic drug monitoring of raltegravir Ctrough levels was carried out in the setting of the Raltegravir Switch for Toxicity or Adverse events (RASTA) trial, a randomized pilot study exploring a 48-week safety and efficacy of treatment switch to ...
Fabbiani, Massimiliano, Cauda, Roberto, Di Giambenedetto, Simona, Navarra, Pierluigi, Ragazzoni, Enzo, Lisi, Lucia, Fortuna, Serena   +6 more
core   +1 more source

Pharmacoeconomic analysis of the etravirine compared to raltegravir in treatment HIV-infected adult patients, previously treated with antiretroviral drugs

Качественная клиническая практика, 2018
Objective: To perform comprehensive pharmacoeconomical assessment of use etravirine and raltegravir in HIV-infected patients. Methodology: Cost-eifectiveness and budget impact analyses of etravirine or raltegravir on the top of optimized background ...
Y. I. Ashikhmin, D. Yu. Belousov
doaj  

Raltegravir [PDF]

, 2020
openaire   +1 more source

Population pharmacokinetics of raltegravir during pregnancy

, 2019
La transmission mère-enfant contribue à 9% des nouvelles infections par le Virus de l'Immunodéficience Humaine (VIH). La décroissance de la charge virale (CV) est le principal facteur pour prévenir la transmission materno-foetale.
Zheng, Yi
core  

Chemoinformatic Approaches to Identify Bioactive Inhibitors Against Type I Dehydroquinase (DHQ1) Enzyme of Typhoidal <i>Salmonella</i>. [PDF]

Bioinform Biol Insights
Ashfaq A, Mariyam S, Aziz U, Mukhtar M, Andleeb S.   +4 more
europepmc   +1 more source